MS-based targeted profiling of oxylipins in COVID-19: A new insight into inflammation regulation

Denise Biagini a,*, Maria Franzini b, Paolo Oliveri c, Tommaso Lomonaco a, Silvia Ghimenti a, Andrea Bonini a, Federico Vivaldi a, Lisa Macera b, Laurence Balas d, Thierry Durand d, Camille Oger d, Jean-Marie Galano d, Fabrizio Maggi e, Alessandro Celi f, Aldo Paolicchi b, Fabio Di Francesco a, **

a Department of Chemistry and Industrial Chemistry, University of Pisa, Italy
b Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Italy
c Department of Pharmacy, University of Genoa, Italy
d Institut des Biomolécules Max Mousseron (IBMM), UMR 5247, University of Montpellier, CNRS, EBNSCM, France
e Department of Medicine and Surgery, University of Insubria, Italy
f Department of Surgical, Medical, Molecular and Critical Area Pathology, University of Pisa, Italy

ARTICLE INFO

Keywords:
COVID-19
Oxylipins
Inflammation regulation
Severity predictors
Lipid mediator class switching
UHPLC-MS/MS

ABSTRACT

The key role of inflammation in COVID-19 induced many authors to study the cytokine storm, whereas the role of other inflammatory mediators such as oxylipins is still poorly understood.

IMPRECOVID was a monocentric retrospective observational pilot study with COVID-19 related pneumonia patients (n = 52) admitted to Pisa University Hospital between March and April 2020. Our MS-based analytical platform permitted the simultaneous determination of sixty plasma oxylipins in a single run at ppt levels for a comprehensive characterisation of the inflammatory cascade in COVID-19 patients. The datasets containing oxylipin and cytokine plasma levels were analysed by principal component analysis (PCA), computation of Fisher’s canonical variable, and a multivariate receiver operating characteristic (ROC) curve.

Differently from cytokines, the panel of oxylipins clearly differentiated samples collected in COVID-19 wards (n = 43) and Intensive Care Units (ICUs) (n = 27), as shown by the PCA and the multivariate ROC curve with a resulting AUC equal to 0.92. ICU patients showed lower (down to two orders of magnitude) plasma concentrations of anti-inflammatory and pro-resolving lipid mediators, suggesting an impaired inflammation response as part of a prolonged and unsolvable pro-inflammatory status. In conclusion, our targeted oxylipidomics platform helped shedding new light in this field. Targeting the lipid mediator class switching is extremely important for a timely picture of a patient’s ability to respond to the viral attack. A prediction model exploiting selected lipid mediators as biomarkers seems to have good chances to classify patients at risk of severe COVID-19.

1. Introduction

Approximately 24 months after the onset of the COVID-19 pandemic, despite the unprecedented effort of the scientific community, there are still many open questions regarding the pathophysiology of the disease, the therapy, and the clinical management of patients.

Severe patients are characterized by a hyper immuno-activation leading generally to respiratory failure, systemic inflammation and multi-organ fibrosis. Markers associated with this acute immune-inflammatory response and severe COVID-19 symptoms could be found among chemicals involved in the cytokine and oxylipin storm [1].

The cytokine storm results in a detrimental dysregulation of T cell responses and in an uncontrolled overproduction of immune cells and cytokines, such as tumour necrosis factor-α (TNF-α), interferon-γ (IFN-γ), interleukins (IL-1β, IL-2, IL-6, IL-7, IL-8), and a large number of chemokines (CCL2, CCL3, CCL5, CCL9, CCL10) [2]. Besides cytokines, other important inflammatory mediators, e.g., oxylipins, sustain the inflammatory response observed in severe COVID-19 cases [3-7].
COVID-19 patients showed higher levels of these mediators compared to healthy subjects [4,5,7]. Bosio et al. suggested a lipid dysregulation from moderate to severe disease. However, neither clear lipidome dysregulation nor significant separation between the two groups was observed [6].

Oxylipins are bioactive lipids generated from both ω-3 and ω-6 polyunsaturated fatty acids (PUFAs) through enzymatic (e.g., prostaglandin, epoxy, and hydroxy fatty acids) and non-enzymatic (e.g., isoprostanooids) oxidation reactions [8,9]. Because of their anti-inflammatory action, ω-3 PUFAs seem to limit the level and duration of the critical inflammatory phase [10], and reduce ICU admissions of COVID-19 patients [11]. At the same time, PUFAs act as precursors for pro-inflammatory, anti-inflammatory, and specialized pro-resolving lipid mediators (SPM) [12,13]. Firstly, pro-inflammatory mediators such as prostaglandins, thromboxanes, and leukotrienes are released into the body, leading to the classic signs of inflammation [14]. The production of oxylipins then undergoes lipid mediator class switching mainly because of CYP450-derived epoxy fatty acids, thus shifting from the lipoxygenase pathway to the specialized pro-resolving mediators [14]. SPMs mostly consist of lipoxins, resolvins, maresins, and pro-resolves, which could lower the inflammatory response and even promote its resolution [15,16] without being immunosuppressive unlike classic anti-inflammatory drugs [17]. Consequently, a better understanding of the cytokine storm and its coupling with the oxylipin storm should provide new insights into the complex immuno-inflammatory cascade induced by SARS-CoV-2 and lead to novel strategies for managing patients. The levels of these bioactive mediators may mirror basic biological processes determining the evolution of the pathology and could provide clinicians with clear indications regarding the urgency of patient transfer to ICU.

In this paper, a powerful in-house oxylipidomics platform was successfully employed for the monitoring of the inflammatory response in COVID-19. In more detail, the plasma levels of 48 oxylipins and 5 cytokines in COVID-19 ward and ICU patients were compared. The results highlighted that the oxylipin plasma levels can be used to discriminate between the two groups by multivariate analysis. A biological interpretation linking the findings of the present study to a possible evolution of the inflammatory process are proposed, shedding new light on the pathophysiological mechanism of the COVID-19 disease.

2. Methods

2.1. Study design and participants

This monocentric retrospective observational study (IMPRE-COVID-19) was approved by the local Ethics Committee. Patients eligible for enrolment were aged 18 years or older and admitted to the University Hospital of Pisa (Pisa, Italy) in March-April 2020 with COVID-19 related pneumonia (wild type). SARS-CoV-2 infection was confirmed by polymerase chain reaction in a nasopharyngeal swab, while pneumonia was demonstrated by CT scan. Members of the Pisa COVID group collected all the clinical information, including co-morbidities, drug intake and routine laboratory data, which were de-identified and stored according to the recommendations of the Ethics Committee and made available to academic researchers. Residuals of plasma samples used for routine clinical measurements were de-identified and stored in the BMS Multi-specialistic Biobank of Pisa University Hospital.

Members of the Pisa COVID group collected a convenient sample of 52 patients randomly selected among those with a complete set of cytokine values evaluated for clinical purposes. In a few cases, plasma samples collected on different days from a single patient were available at the biobank and were analysed to understand the evolution over time of the oxylipin levels during hospitalization.

2.2. Procedures

2.2.1. Virological tests

Viral nucleic acids were manually extracted from 250 μL of plasma or serum samples using the EXTRA blood kit (ELITechGroup, Turin, Italy) according to the manufacturer’s instructions. After extraction, purified RNA samples were screened by RT-qPCR using the SARS-CoV-2 R-Gene assay (Biomerieux, Marcy-l’Etoile, France) on an ABI 7500 FAST thermocycler (Applied Biosystems). The real-time SARS-CoV-2 R-Gene assay is carried out by two triplex PCRs. The first PCR detects the N gene and the RdRp gene whereas the second PCR detects the E gene of the SARS-CoV-2 genome. The assay contains internal controls to check PCR processing, and a cellular control to check sampling for certain results.

2.2.2. Sample collection and processing

Peripheral blood samples were collected from COVID-19 ward and ICU patients with COVID-19 during their hospitalization, as part of the routine clinical activity of the Laboratory of Clinical Pathology of Pisa University Hospital. Whole blood was collected in EDTA tubes (BD Vacutainer®) and centrifuged at 1500 g for 10 min at 25 °C to separate blood cells and plasma. Plasma was removed and stored in aliquots at −80 °C until analysis. For the oxylipin analyses, the antioxidant butylhydroxytoluene (BHT, 15 mg/mL in methanol) was added before storage (BHT-sample volume ratio of 1:100) to preserve polyunsaturated fatty acids from in vitro lipid peroxidation. Before oxylipin analysis, plasma samples were checked to identify SARS-CoV-2 virus. Positive samples were excluded from the quantification of the oxylipin content for safety reasons.

2.2.3. Quantification of oxylipins

The MS-based targeted profiling of 60 oxylipins (e.g., prostaglandins, lipoxins, resolvins, maresins, epoxy- and hydroxy-fatty acids, F2-isoprostanes, F3-isoprostanes, F2-dihomo-isoprostanes, and F3-neuroprostane) [18–20] was performed using micro-extraction by packed sorbent (MEPS) ultra-high performances liquid chromatography tandem mass spectrometry (MEPS-UPHLC-MS/MS) platform [21–23]. Briefly, plasma proteins were precipitated by the sequential addition of salts (i.e., 250 μL of CuSO4·5H2O 10% w/v and 250 μL of Na2WO4·H2O 12% w/v) and acetonitrile (500 μL) to the plasma sample (500 μL). The supernatant was then diluted (1:6 v/v) with water and loaded onto the MEPS C18 cartridge. The cartridge was activated by drawing and discharging 3 times 100 μL of methanol (3 × 100 μL), and then conditioned with 3 × 100 μL of water at 0.6 mL/min. The diluted supernatant (3000 μL) was loaded up and down twelve times at 0.3 mL/min by discarding it. The cartridge was then washed with 100 μL of a water:methanol mixture (95:5 v/v) at 0.6 mL/min to remove potential interferences. Analytes were eluted with 30 μL of methanol at 0.3 mL/min and then injected into the UHPLC-MS/MS instrument. We employed an Agilent 1290 Infinity II LC system coupled to a 6495 Triple Quadrupole mass spectrometer, which was equipped with a Jet Stream electrospray (ESI) ionization source (Agilent Technologies, USA). The chromatographic separation was achieved using a Polaris 3C18-A column (50 × 4.6 mm, 3 μm, Agilent Technologies, USA) and a gradient elution with a mobile phase consisting of 0.1% aqueous formic acid and 50:50 v/v methanol:acetonitrile. The mass spectrometer operated in ESI negative ionization mode and performed multiple reaction monitoring (MRM) with unit mass resolution. Detailed chromatographic parameters, ESI and MRM conditions for each compound are shown in the Supporting Information (Table S1). Compounds were quantified by calibration curves plotting the analyte to an internal standard peak area ratio (Quantifier transition) versus the corresponding concentration ratio. Table S2 lists the main analytical figures of merit of the MEPS-UPHLC-MS/MS platform. Fig. S1 shows the chromatographic profiles for the sixty oxylipins.

2.2.4. Quantification of cytokines

Plasma cytokines (i.e., IL-6, IL-1β, IL-10, TNF-α, and CCL2) and
granulocyte-macrophage colony-stimulating factor (GM-CSF) were quantified by automated ELISA assays according to the manufacturer’s instructions (see supplementary information).

2.3. Statistical analysis

Datasets D1 and D2, which include the plasma levels of 48 oxylipins (Table S3) and 5 cytokines (IL-6, IL-1β, IL-10, TNF-α, and CCL2, Table S4), respectively, were obtained from the analyses of 70 samples collected from patients hospitalised in COVID-19 wards (patients = 32, samples = 43) and ICUs (patients = 24, samples = 27) (four patients were in both groups). Twelve out of sixty oxylipins (Table S2) were excluded from D1 as the concentrations were below the limit of quantification for more than 50% of samples. A decimal logarithmic transformation was used to correct for asymmetry characterising all the variables [24]. Samples were randomly split into a training (n = 56) and a test set (n = 14): the former was used to build the models and the latter to independently estimate performances and consistency.

Data were analysed by a multivariate exploratory method (principal component analysis, PCA) [25,26]. In the present study, PCA was applied after column autoscaling to ensure the same importance a priori to be given to all variables, irrespectively of their magnitude [27].

Fisher’s canonical variable was then computed in the plane described by the two lowest-order PCs, as the direction that maximises the ratio between inter-class and intra-class variances [28]. This axis represents the most discriminant direction, and its loadings, multiplied by the loadings of the PCs considered, indicate the importance of the original input variables in the differentiation of the classes.

Finally, a multivariate receiver operating characteristic (ROC) curve was obtained by varying the confidence level of unequal class models and computing, at each step, sensitivity and specificity [29–31]. Multivariate data processing was performed by in-house Matlab routines (The MathWorks, Inc., Natick, USA, Version 2019b).

3. Results

Between 1 March and 30 April 2020, 52 patients were admitted to Pisa University Hospital, 28 in COVID-19 wards, 20 in ICUs and 4, initially hospitalised in COVID-19 wards, who were then transferred to the ICUs due to deteriorating health conditions. The clinical characteristics, comorbidities and outcome of patients are reported in Table 1.

Baseline characteristics were generally similar between the two groups, with the exception of diabetes prevalence, which was higher in ICU patients, and of the Horowitz index for lung function (P/F ratio) that identified the acute hypoxemic respiratory condition of ICU patients. These patients were also characterized by leucocytosis, lymphocytopenia and higher D-dimer levels, which were all related to the enhanced inflammatory response and more severe viral infection. Pharmacological therapy was similar in the two-study group except for the antiretroviral drugs that were more represented in the ward group.

The full data-set concerning the plasma concentrations of oxylipins and cytokines are reported in Table S3 and Table S4, respectively. A clear separation of samples collected from COVID-19 wards (blue symbols) and ICUs (red symbols) is visible in the oxylipin score plot (Fig. 1a), whereas it is not observed in the case of cytokines (Fig. 1b). This pattern is consistent for items of both the training set (full symbols), used to build the model and calculate PCs, and the test set (empty symbols), which were simply projected onto the PC plane [24] for validation purposes.

Interestingly, many borderline samples were collected from COVID-19 ward patients who were subsequently transferred to the ICUs a few days after sample collection due to their deteriorating health conditions. Samples collected from the same patient on different days (stars) are connected by coloured arrows: shifts in the oxylipin score plot from the blue to the red zone seem to replicate the movements of patients from COVID-19 wards to the ICUs, however this is not reflected in the cytokine score plot.

Fig. 1a shows that PCI scores provide the main contribution (about 38% of the total variance) to the separation of the two sample classes, though PCI2 also contributes for about 10%. To understand which oxylipins differentiate samples, the most discriminant direction was computed as Fisher’s canonical variable (full black line), whose loadings describe the two lowest-order PCs, as the direction that maximises Fisher’s canonical variable (full black line), whose loadings described by the loadings of the PCs considered, indicate the importance of the original input variables in the differentiation of the classes.

Finally, a multivariate receiver operating characteristic (ROC) curve was obtained by varying the confidence level of unequal class models and computing, at each step, sensitivity and specificity [29–31]. Multivariate data processing was performed by in-house Matlab routines (The MathWorks, Inc., Natick, USA, Version 2019b).

Table 1

| Comorbidities                  | W (n = 32) | ICU (n = 20) | p     |
|-------------------------------|------------|-------------|-------|
| Diabetes (n; %)               | 1; 3       | 5; 25       | 0.0263|
| Hypertension (n; %)           | 10; 31     | 7; 25       | 0.7630|
| COPD/asthma (n; %)            | 2; 9       | 0; 0        | 0.2760|
| Hypercholesterolemia (n; %)   | 4; 13      | 4; 20       | 0.6949|
| Heart disease (n; %)          | 13; 41     | 3; 15       | 0.0679|
| Drugs                         |            |             |       |
| Lopinavir plus ritonavir (n; %)| 29; 91     | 13; 65      | 0.0327|
| Remdesivir (n; %)             | 1; 3       | 3; 15       | 0.2855|
| Corticosteroids (n; %)        | 11; 34     | 12; 60      | 0.0901|
| Tocilizumab (n; %)            | 7; 22      | 1; 5        | 0.1324|
| Baricitinib (n; %)            | 5; 16      | 4; 20       | 0.7151|
| Heparin (n; %)                | 22; 69     | 16; 80      | 0.5237|

Clinical characteristics

| Age, years | W (n = 32) | ICU (n = 20) | p     |
|------------|------------|-------------|-------|
| P/F admission, mmHg | 313 (263 – 377) | 256 (207-327) | 0.0215|
| P/F nadir, mmHg     | 182 (95 – 288) | 96 (72 – 118) | 0.0055|
| SOFA score          | 2.0 (1.0 – 3.0) | 2.0 (1.8 – 3.3) | 0.3724|
| Creatinine, mg/dL   | 0.98 (0.80 – 1.27) | 1.13 (0.83 – 1.46) | 0.4274|
| While blood cells, cells/µL | 5.9 (4.5 – 7.8) | 8.0 (6.9 – 11.9) | 0.0117|
| Neutrophils, cells/µL | 3.8 (2.9 – 5.8) | 6.1 (3.7 – 8.3) | 0.0623|
| Lymphocytes, cells/µL | 1.1 (0.7 – 1.3) | 0.6 (0.5 – 1.1) | 0.0309|
| C-reactive protein, mg/dL | 5.7 (2.8 – 11.0) | 8.8 (3.1 – 13.6) | 0.4470|
| D-Dimer, µg/mL       | 0.35 (0.19 – 0.52) | 0.65 (0.27 – 1.26) | 0.0166|

Outcome

| Survived (n; %) | W (n = 32) | ICU (n = 20) | p     |
|----------------|------------|-------------|-------|
| Survived (n; %) | 27; 84     | 17; 85      |       |
| ETV (n; %)     | 0; 0       | 12; 60      |       |
Eicosatetraenoic acid as HETEs and HODE (e.g. 15-HETE: ICU [0.861 ng/mL (0.562–4.51)] vs. W [24.7 ng/mL (2.56–82.8)], p = 1.37E-08), dihydroxyeicosatetraenoic acid (DiHETEs) epoxy-eicosatrienoic acid (EETs), lipoxins, and SPMs as resolvins, protectins, maresin (e.g. resolvin-D5: ICU [0.091 ng/mL (0.038–0.489)] vs. W [1.73 ng/mL (0.632–3.95)], p = 3.88E-08). Only the multivariate analysis of oxy-lipins provides such a clear separation between the two classes of samples, whereas individual variables exhibit a lower discriminant capability (see scatter column plots for individual oxylipins in Fig. 3).

To further confirm the classification capacity of the full oxylipin set, a multivariate ROC curve was obtained by the UNEQ class-modelling strategy (Fig. 3). The multivariate model was computed using the four lowest-order PCs as the input variables and COVID-19 ward samples as the target class. The resulting area under the curve (AUC, 0.92) exceeded...
two groups fits well with our present understanding of COVID-19 and blood test, e.g., age, comorbidities, oxygen saturation, lactate dehydrogenase on clinical parameters easily measured or calculated from a routine proposed scores are based on demographic and anamnestic data as well relative contributions of individual oxylipins to the classification of the patients in different wards and ICUs. In addition, the analysis of the borderline samples were collected from COVID-19 ward patients that was not achieved by processing cytokine values. The fact that many separation was not achieved by processing cytokine values. The fact that many borderine samples were collected from COVID-19 ward patients that were about to be transferred to ICUs suggests that sample differences were not a trivial consequence of different treatments received from patients in different wards and ICUs. In addition, the analysis of the relative contributions of individual oxylipins to the classification of the two groups fits well with our present understanding of COVID-19 and may provide new insights into its pathophysiology.

Several papers have been published in the last year discussing factors related to the severity of COVID-19 and defining risk scores for the prediction of severity and outcome of the disease [32–35]. Most of the proposed scores are based on demographic and anamnestic data as well as on clinical parameters easily measured or calculated from a routine blood test, e.g., age, comorbidities, oxygen saturation, lactate dehydrogenase or neutrophil-to-lymphocyte ratio. If from one side this makes these scores practical for clinical use, on the other it does not provide any improved understanding on the pathophysiological mechanism of the disease or information relevant to the evolution of the biological processes occurring in the patient.

In our case, ICU patients showed almost comparable levels of pro-inflammatory iso prostanooids produced from the non-enzymatic oxidation of PUFAs such as AA, DHA and EPA, and a pronounced and selective deficiency of oxylipins such as prostaglandins, leukotrienes, anti-inflammatory, and pro-resolving oxylipins originating from their enzymatic conversion. The isoprostanooid 4(R,S)-4-F_2t-neuroprostane was down-regulated in ICU patients (ICU [0.026 ng/mL (0.020–0.074)] vs. W [0.238 ng/mL (0.092–0.594)], p = 1.39E-05). This lipid mediator prevents oxidation of the RyR ryanodine receptors, a family of Ca^{2+} release channels that controls the intracellular calcium exchange and whose oxidation may cause leaks of Ca^{2+} and lead to heart failure, pulmonary insufficiency and cognitive dysfunction in COVID-19 [36]. Furthermore, TX-B_2 was the only prostanooid with an enzymatic origin over-expressed in ICU patients, which agrees with the need for heparin therapy in these patients to prevent microcirculatory damage.

Inflammation is a highly coordinated transcriptional process whose evolution towards resolution or persistence depends on a dynamic balance between pro- and anti-inflammatory mediators. In a controlled inflammatory process, immune tissue-resident cells activate processes producing chemokines and cytokines. Endothelial cells then respond thereby facilitating the recruitment of neutrophils (first) and monocytes (at a later stage), which differentiate into pro-inflammatory M1 macrophages (Fig. 4) [37]. Pro-inflammatory cytokines activate the phospholipase A2 enzymes, which cause the release from membranes of AA, which is then converted into prostanoids or leukotrienes by cell-specific enzymatic activities. This phase is characterized by a prevalence of COX-2, both in neutrophils and M1-macrophages, and 5-LOX activity, above all in neutrophils. COX-2 and 5-LOX are responsible for the production of prostaglandins (PGD_2 and PGE_2) and leukotrienes (LTs), respectively [38].

The switch of lipid mediators from prostanooids to lipoxins and SPMs (i.e., resolvins, protectins, and maresins) is critical for inflammation resolution [39]. In fact, PGE_2 facilitates the transformation of pro-inflammatory M1 into anti-inflammatory M2-macrophages characterized by the up-regulation of the 15-LOX enzyme, which is primarily involved in the synthesis of SPMs [40]. PGE_2 also helps to switch the pro-inflammatory (e.g., TNF-α, IL-1β, and IL-6) into the anti-inflammatory interleukins synthetized by M2-macrophages (e.g., IL-10) [41]. The intermediate products of 5-LOX and 15-LOX activities (5-HPTEs and 5-HETE; 15-HPTE and 15-HETE) are also precursors for the biosynthesis of lipoxins LXA_4 and LXB_4, which are important agonists of the resolution of inflammation since they inhibit neutrophil recruitment, stimulate vasodilation, and promote effecotyosis [41].

Together with prostanooids, neutrophils play a key role in the modulation of the macrophage function through the release of apoptotic bodies and microvesicles. In fact, the phagocytosis of the microvesicles by M1 macrophages is essential to trigger their functional reprogramming into M2-macrophages (Fig. 4) [42].

For these reasons, we speculate that the oxylipin pattern observed in ICU patients affected by severe COVID-19 mirrors an impaired inflammation response which is part of a prolonged and unsolvable pro-inflammatory status characterized by a relative lack of oxylipins produced from the enzymatic processing of PUFAs. The impaired production of anti-inflammatory and pro-resolving oxylipins is not a consequence of the reduced availability of PUFA precursors, which appear unchanged or even increased in ICU patients. The presence of soluble isoprostanoids in both classes of patients confirms that the availability of membrane PUFAs is not a limitation for their enzymatic processing [43].

Much remains to be understood regarding the pathogenetic mechanism of COVID-19, however defective innate and specific immune responses are likely to be critical features [44]. Schulte-Schrepping et al. [45] showed an increase in dysfunctional neutrophils and monocytes in severe COVID-19 patients that seems to be in agreement with our findings.

A massive endothelial dysfunction resulting from the cytokine storm and the infiltration of SARS-CoV-2 is a further characteristic of severe COVID-19 that determines the loss of vessel barrier, the promotion of leukocyte infiltration, and the activation of platelet aggregation and coagulation [44,46]. Interestingly, in ICU patients we found higher levels of TX-B_2, the biological inactive catabolite of TX-A_2 (a potent activator of platelet aggregation and thus of coagulation). This is in line with the diffused microthrombosis observed in COVID-19 [44,47] and with the lower levels of EETs, which are mainly produced by endothelial epoxygenase and are important mediators of all pro-resolving mechanisms [48], including the lipid mediator class switching [49,50].

In conclusion, our powerful in-house oxylipidomics platform revealed that the more severe disease in ICU patients is accompanied by an inefficient enzymatic synthesis of the anti-inflammatory oxylipins.
resulting in an ineffective resolution mechanism of inflammation, likely worsened by endothelial damage. This hypothesis, once supported by prospective studies, might provide a basis for the identification of early biomarkers of poor disease outcome. In addition, the possible imbalance between the production of anti-inflammatory and pro-resolving oxylipins in ICU patients might explain the poor outcome of therapies based on cytokine inhibitors, and opens up new perspectives for the therapy of severe COVID-19 and, in general, of lung diseases.

Data sharing

All de-identified data will be shared upon approval from the IMPRE-COVID-19 steering committee and a signed data access agreement. All requests should be sent to denise.biagini@dcci.unipi.it.

Author contributions

DB, FM, AP and FDF designed the study. DB, TL and SG developed the method for the analysis of oxylipins, LB, TD, CO and JMG synthesized 22 oxylipins needed for calibration that were not commercially available, DB, FV and AB measured oxylipin levels, MF measured cytokine levels whereas LM performed virological tests. PO performed data analysis, MF, AC and AP provided biological and clinical interpretation of data. DB, MF, PO and FDF drafted the paper, all the authors revised the paper.

Fig. 4. Cellular and oxylipin interplay during the evolution of an inflammatory process. Phase 1 and Phase 2: rapid neutrophil and delayed monocyte extravasation in response to cytokines produced by activated immune tissue-resident cells. Pro-inflammatory oxylipins are produced mainly by neutrophils, M1-macrophages, activated endothelial cells and platelets. Phase 3: neutrophil apoptotic bodies and prostaglandins promote the macrophage shift towards a resolution-phase function. Phase 4: inflammation resolution is promoted by increasing production of the specialized pro-resolving mediators. PGE$_2$: prostaglandin E$_2$; PGD$_2$: prostaglandin D$_2$; PGJ$_2$: prostacyclin I$_2$; TX-A$_2$: thromboxane A$_2$; LTA$_4$: leukotriene A$_4$; LTB$_4$: leukotriene B$_4$; Cys-LT: cysteine-leukotrienes; EETs: epoxyeicosatrienoic acids; COX-1: cyclooxygenase-1; COX-2: cyclooxygenase-1; 5-LOX: 5-lipoxygenase; 15-LOX: 15-lipoxygenase.

Funding

Institutional funds from the University of Pisa supported the study.

Role of the funding source

The funders of the study had no role in the study design, data collection, data analysis, data interpretation, or writing of the report. All the authors had full access to all data and shared the final responsibility for the decision to submit for publication.

Declaration of competing interest

The authors declare no competing interests.

Acknowledgments

Members of the Pisa COVID group are gratefully acknowledged for collecting the clinical information, Dr. Simone Lapi and the BMS Multispecialistic Biobank of Pisa University Hospital are acknowledged for supplying the plasma samples. The study received financial support from institutional funds of the University of Pisa.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.freeradbiomed.2022.01.021.
overexpression and soluble epoxide hydrolase disruption attenuate acute vascular inflammatory responses in mice, Faseb. J. 25 (2011) 703–713.

[49] E. Ono, S. Dutile, S. Kazani, M.E. Wechsler, J. Yang, B.D. Hammock, D.N. Douda, Y. Tabet, R. Khaddaj-Mallat, M. Sirois, Lipoxin generation is related to soluble epoxide hydrolase activity in severe asthma, Am. J. Respir. Crit. Care Med. 190 (2014) 886–897.

[50] S.M. Shoieb, M.A. El-Ghiaty, A.O.S. El-Kadi, Targeting arachidonic acid-related metabolites in COVID-19 patients: potential use of drug-loaded nanoparticles, (n. d.), https://doi.org/10.1007/s42247-020-00136-8/Published.
MS-based targeted profiling of oxylipins in COVID-19: a new insight into inflammation regulation

Denise Biagini1*, Maria Franzini2, Paolo Oliveri3, Tommaso Lomonaco1, Silvia Ghimenti1, Andrea Bonini1, Federico Vivaldi1, Lisa Macera2, Laurence Balas4, Thierry Durand4, Camille Oger4, Jean-Marie Galano4, Fabrizio Maggi5, Alessandro Celi6, Aldo Paolicchi2, Fabio Di Francesco1*

1Department of Chemistry and Industrial Chemistry – University of Pisa
2Department of Translational Research and New Technologies in Medicine and Surgery – University of Pisa
3Department of Pharmacy – University of Genoa
4Institut des Biomolécules Max Mousseron (IBMM), UMR 5247, University of Montpellier, CNRS, EBNSCM
5Department of Medicine and Surgery – University of Insubria
6Department of Surgical, Medical, Molecular and Critical Area Pathology - University of Pisa

*Corresponding authors: denise.biagini@dcci.unipi.it; fabio.difrancesco@unipi.it
SUPPLEMENTARY INFORMATION

Materials

Detection of SARS-CoV-2 RNA
An EXTRAblood kit (ELITechGroup, catalogue number EXTB01, United Kingdom) was employed according to the manufacturer’s instructions for the manual extraction of viral nucleic acids from plasma (or serum) samples. After extraction, purified RNA samples were screened using the SARS-CoV-2 R-Gene assay (Biomerieux, Marcy l’Etoile, France) and the 7500 Fast instrument (Applied Biosystems).

Quantitation of cytokines
IL-6 was quantified by Human IL-6 Instant ELISA Kit (Invitrogen, ThermoFisher Scientific), IL-1β by Human IL-1β Instant ELISA (eBioscience, Affimetryx), IL-10 by Human IL-10 Instant ELISA Kit (Invitrogen, ThermoFisher Scientific), TNF-α by Human TNF-α Quantikine® ELISA Kit (R&D System, Minneapolis, Canada), CCL2 by Human CCL2/MCP-1 Quantikine® ELISA Kit (R&D System, bio-techne), and GM-CSF by Human GM-CSF Instant ELISA kit (Invitrogen, ThermoFisher Scientific).

Quantification of oxylipins
Commercially available oxylipins, 15-F2t-isoprostane, 15-F2t-isoprostane-d4, 15-E2t-isoprostane, 15-E2t-isoprostane-d4, prostaglandin E2, prostaglandin E2-d4, prostaglandin D2, 15-deoxy-Δ12,14-Prostaglandin J2, thromboxane B2, leukotriene B4, lipoxin A4, lipoxin A4-d5, lipoxin B4, resolin E1, resolin D1, resolin D1-d5, resolin D2, resolin D3, resolin D4, 17(R)-Resolin-D1, 17(R)-Resolin-D1-d5, 17(R)-Resolin-D2, 17(R)-Resolin-D2-d4, neuroprotectin D1, protectin DX, maresin-1, maresin-1-d5, 7-epi-maresin-1, maresin-2, 5-hydroxyeicosatetraenoic acid (HETE), 12-HETE, 15-HETE, 20-HETE, 20-HETE-d6, 8,9-DiHETE, 11,12-DiHETE, 13-hydroxy-9Z,11E-octadecadienoic acid (HODE), 8,9-epoxyeicosatrienoic acid (EET), 11,12-EET, 14,15-EET, 14,15-EET-d11, adrenic acid (AdA), eicosapentaenoic acid (EPA), alpha-linolenic acid (ALA) docosahexanoic acid (DHA), arachidonic acid (AA), docosapentaenoic acid (DPA), linoleic acid (LA) and LA-d4 (purity ≥99%) were from Cayman Chemical (Michigan, USA). Not commercially available oxylipins, i.e. 5-F2t-isopostane, 5-epi-5-F2t-isoprostane, 8-F2t-isoprostane, 8-epi-8-F2t-isoprostane, 18-F3t-isoprostane, 20-F2t-neuroprostane, 20-epi-20-F2t-neuroprostane, 10-F4t-neuroprostane-d4, 10-epi-10-F4t-neuroprostane-d4, 14(R,S)-14-F4t-neuroprostane, 14(R,S)-14-F3t-neuroprostane, 4(R,S)-4-F4t-neuroprostane, C21-15-F3t-isoprostane, tetranor-NPD1, dinor-NPD1, 7(R,S)-ST-Δ3,11-dihomo-isofuran, ent-7(R,S)-7-F2t-dihomo-isoprostane, 17-F2t-dihomo-isoprostane, linotrin, diHb,4-DPA, diHb,6-DPA and diH-AdA were synthesized at the Institut des Biomolecules Max Mousson (IBBM) (Montpellier, France), according to procedures reported elsewhere (1–3).

All the solutions and plasma samples were stored in sterile polypropylene containers from Eppendorf (Milan, Italy). Phenex™-RC syringe filters (0.2 μm regenerate cellulose, 15 mm of diameter) were from Phenomenex (California, USA). A VELP Scientifica ZX4 Advanced Vortex Mixer (Usmate, Italy) and a Hermle Z-326 K Centrifuge, (Wehingen, Germany) were used for sample vortex-mixing and centrifugation, respectively. The removable needle micro-extraction by packed sorbent (MEPS) 250 μL syringe for HTA 300APlus (Thermo Scientific & Varian 8400 systems) and MEPS silica-C18 Barrel Insert and Needles (BINS) were purchased from SGE Analytical Science (Melbourne, Australia). The automated HT4000 Series Sample Prep workstation was purchased from HTA S.R.L. (Brescia, Italy).
**Chromatographic separation of oxylinps, ESI and MRM operating conditions**

The chromatographic separation was achieved at 0.7 mL min\(^{-1}\) using a Polaris 3 C18-A column (50 x 4.6 mm, 3 μm, Agilent Technologies, USA) and a mobile phase consisting of 0.1% aqueous formic acid (A) and 50:50 v/v methanol:acetonitrile (B). The linear gradient was as follows: 10% (B) for 2 min, 45% (B) at 2.1 min, isocratic for 3 min, from 45% to 60% (B) in 3.5 min, isocratic for 0.5 min, from 60 to 80% (B) in 2 min, isocratic up to 11.1 min at 0.4 mL min\(^{-1}\), from 80 to 90% (B) in 10 min, re-equilibration to initial conditions up to 26 min. The multisampler and the column compartment were set at a 4 and 25 °C, respectively. The injection volume was 20 μL. The Agilent 6495 Triple Quadrupole mass spectrometer detector operated in ESI negative ionization mode and performed multiple reaction monitoring with unit mass resolution. For all analytes, the ESI operation conditions were: drying gas temperature 240 °C, drying gas flow 18 L min\(^{-1}\), nebulizer gas pressure 30 psi (25 psi from 9.5 min up to the end of the run), sheath gas temperature 360 °C, sheath gas flow 12 L min\(^{-1}\), capillary voltage 5000 V (2500 V from 9.5 min up to the end of the run) and nozzle 1500 V. The fragmentor voltage was fixed at 380 V and high and low pressure funnel voltages were set at 160 and 160 V (90 and 90 V from 9.5 min up to the end of the run) for all mass transitions. Each analyte was detected using two specific MRM transitions, the most abundant of those transitions was used for quantification (Q), whereas the second one for the identification of the target compound (q). A deviation of ± 0.10 min of the expected retention time compared to working standard solutions and a qualifier/quantifier (q/Q) ratio within 10% of the ratio measured in working standard mixtures were required for analyte identification. The selected MRM transitions, the collision energy and the labelled ISTDs used for analyte normalization are reported below.
| Compound   | Internal standard | MRM quantifier (Q) transition (precursor ion → product ion (CE, V)) | MRM qualifier (q) transition (precursor ion → product ion (CE, V)) |
|------------|------------------|---------------------------------------------------------------|---------------------------------------------------------------|
| **PUFAs**  |                  |                                                               |                                                               |
| AA         | LA-d4            | 303 → 259 (12)                                                | 303 → 285 (28)                                                |
| AdA        | LA-d4            | 331 → 331 (1)                                                 |                                                               |
| DHA        | LA-d4            | 327 → 283 (8)                                                 | 327 → 229 (10)                                                |
| DPA        | LA-d4            | 329 → 285 (12)                                                | 329 → 231 (8)                                                 |
| EPA        | LA-d4            | 301 → 257 (12)                                                | 301 → 203 (16)                                                |
| LA         | LA-d4            | 279 → 279 (1)                                                 |                                                               |
| alpha-LA   | LA-d4            | 277 → 277 (1)                                                 |                                                               |
| **Isoprostanooids (IsoPs, NeuroPs, dihomo-IsoPs), isofurans (IsoFs) and prostanooids (prostaglandins (PGs), leukotrienes (LEU), thromboxanes (TX))** | | |
| 5-F_{22}-IsoP | 15-F_{22}-IsoP-d4 | 353 → 309 (20)                                               | 353 → 115 (31)                                               |
| 5-epi-5-F_{22}-IsoP | 15-F_{22}-IsoP-d4 | 353 → 309 (20)                                               | 353 → 115 (31)                                               |
| 15-F_{22}-IsoP | 15-F_{22}-IsoP-d4 | 353 → 193 (28)                                               | 353 → 309 (20)                                               |
| 8-F_{22}-IsoP | C21 15-F_{22}-IsoP | 351 → 127 (28)                                               | 351 → 135 (28)                                               |
| 8-epi-8-F_{22}-IsoP | C21 15-F_{22}-IsoP | 351 → 127 (28)                                               | 351 → 135 (28)                                               |
| 18-F_{22}-IsoP | C21 15-F_{22}-IsoP | 351 → 233 (28)                                               | 351 → 289 (28)                                               |
| 15-E_{22}-IsoP | 15-E_{22}-IsoP-d4 | 351 → 315 (8)                                                | 351 → 271 (28)                                               |
| 14(R.S)-4,8-F_{22}-NeuroP | 10-F_{22}-NeuroP-d4 | 377 → 271 (25)                                               | 377 → 101 (25)                                               |
| 20-F_{22}-NeuroP | 10- F_{22}-NeuroP-d4 | 377 → 239 (27)                                               | 377 → 323 (27)                                               |
| 20-epi-20-F_{22}-NeuroP | 10-epi-F_{44}-NeuroP-d4 | 377 → 271 (28)                                               | 377 → 315 (28)                                               |
| 14(R.S)-14,15-F_{22}-NeuroP | 10- F_{22}-NeuroP-d4 | 377 → 161 (28)                                               | 377 → 205 (28)                                               |
| 14(R.S)-14,15-F_{22}-NeuroP | 10- F_{22}-NeuroP-d4 | 379 → 179 (30)                                               | 379 → 207 (30)                                               |
| ent-7(R.S)-7-F_{22}-dihomo-isof | 17(R)-Resolvin-D_{1},d5 | 381 → 143 (34)                                               | 381 → 119 (34)                                               |
| 7(R.S)-dihomo-isof | 17(R)-Resolvin-D_{1},d5 | 381 → 337 (31)                                               | 381 → 237 (31)                                               |
| 7(R.S)-ST-A^* 11-dihomo-isof | 17(R)-Resolvin-D_{1},d5 | 397 → 201 (36)                                               | 397 → 143 (36)                                               |
| PGE_{2}     | PGE_{d4}         | 351 → 315 (8)                                                 | 351 → 271 (28)                                               |
| PGD_{2}     | PGE_{d4}         | 351 → 315 (12)                                                | 351 → 271 (20)                                               |
| 15-deoxy-A^{15,16}-Prostaglandin J_{1} | PGE_{d4} | 315 → 271 (12)                                               | 315 → 203 (24)                                               |
| LEU-B_{1}   | Maresin 1-d5     | 335 → 195 (16)                                                | 335 → 317 (16)                                               |
| TX-B_{2}    | 15-F_{22}-IsoP-d4 | 369 → 195 (12)                                                | 369 → 169 (20)                                               |
| **Hydroxy/dihydroxy-PUFAs** | | | |
| 5-HETE      | 20-HETE-d6       | 319 → 115 (12)                                                | 319 → 257 (12)                                               |
| 12-HETE     | 20-HETE-d6       | 319 → 179 (12)                                                | 319 → 208 (12)                                               |
| 15-HETE     | 20-HETE-d6       | 319 → 219 (12)                                                | 319 → 175 (16)                                               |
| 20-HETE     | 20-HETE-d6       | 319 → 289 (16)                                                | 319 → 245 (16)                                               |
| 15-HODE     | 20-HETE-d6       | 295 → 277 (20)                                                | 295 → 195 (16)                                               |
| 8,9-DiHETE  | Maresin 1-d5     | 335 → 185 (16)                                                | 335 → 127 (24)                                               |
| 11,12-DiHETE | Maresin 1-d5     | 335 → 167 (16)                                                | 335 → 207 (20)                                               |
| 14,15-DiHETE | Maresin 1-d5     | 335 → 317 (12)                                                | 335 → 207 (20)                                               |
| **Epoxy-PUFAs** | | | |
| 8(9)-EET    | 14(15)-EET-d11   | 319 → 155 (12)                                                | 319 → 257 (8)                                                |
| 11(12)-EET  | 14(15)-EET-d11   | 319 → 167 (12)                                                | 319 → 179 (12)                                               |
| 14(15)-EET  | 14(15)-EET-d11   | 319 → 219 (8)                                                 | 319 → 257 (8)                                                |
| **Pro-resolving (lipoxins, resolvinS, maresins, protectins)** | | | |
| Lipoxin-A_{1} | Lipoxin-A_{1}-d5 | 351 → 115 (16)                                                | 351 → 235 (14)                                               |
| Lipoxin-B_{1} | Lipoxin-A_{1}-d5 | 351 → 221 (16)                                                | 351 → 233 (16)                                               |
| Resolvin-D_{1} | Resolvin-D_{1}-d5 | 375 → 141 (14)                                                | 375 → 233 (14)                                               |
| Resolvin-D_{2} | Resolvin-D_{2}-d5 | 375 → 175 (18)                                                | 375 → 141 (14)                                               |
| Resolvin-D_{3} | Resolvin-D_{3}-d5 | 375 → 147 (18)                                                | 375 → 191 (18)                                               |
| Resolvin-D_{4} | Resolvin-D_{4}-d5 | 375 → 101 (16)                                                | 375 → 357 (16)                                               |
| Resolvin-D_{5} | Maresin 1-d5     | 359 → 199 (16)                                                | 359 → 279 (16)                                               |
| 17(R)-Resolvin-D_{1} | 17(R)-Resolvin-D_{1}-d5 | 375 → 141 (14)                                               | 375 → 233 (14)                                               |
| 17(R)-Resolvin-D_{2} | 17(R)-Resolvin-D_{2}-d5 | 375 → 147 (18)                                               | 375 → 191 (18)                                               |
| 17(R)-Resolvin-D_{3} | 17(R)-Resolvin-D_{3}-d5 | 375 → 101 (16)                                               | 375 → 357 (16)                                               |
| Resolvin-E_{1} | Resolvin-E_{1}-d5 | 349 → 195 (16)                                                | 349 → 205 (16)                                               |
| Maresin-1   | Maresin 1-d5     | 359 → 177 (16)                                                | 359 → 250 (16)                                               |
| Compound                  | Maresin 1-d5     | 359 → 250 (18) | 359 → 177 (18) |
|--------------------------|------------------|----------------|----------------|
| 7-epi-maresin-1          | Maresin 1-d5     | 359 → 221 (14) | 359 → 232 (16) |
| Neuroprotectin D₁        | Maresin 1-d5     | 359 → 206 (14) | 359 → 153 (14) |
| Dinor-Neuroprotectin D₁  | Maresin 1-d5     | 333 → 315 (14) | 333 → 206 (21) |
| Tetranor-Neuroprotectin D₁| Maresin 1-d5     | 305 → 243 (16) | 305 → 192 (16) |
| Protectin DX             | Maresin 1-d5     | 359 → 153 (14) | 359 → 206 (14) |
| diH-AdA                  | Maresin 1-d5     | 363 → 345 (21) | 363 → 208 (21) |
| diH₅-6-DPA               | Maresin 1-d5     | 361 → 263 (16) | 361 → 206 (18) |
| diH₆-6-DPA               | Maresin 1-d5     | 361 → 153 (18) | 361 → 208 (21) |
| Linotrin                 | Maresin 1-d5     | 309 → 291 (21) | 309 → 171 (21) |
**Table S2. Full list of quantified oxylipins and relevant analytical parameters (calibration curve, limit of detection, intra-assay and inter-assay recovery, intra-assay and inter-assay precision.**

| Compound | Calibration levels (pg/mL, ng/mL) | Slope ± s.d. (R²) | LOD (pg/mL, ng/mL) | Intra-assay recovery % (RSD) | Inter-assay recovery % (RSD) |
|----------|----------------------------------|-------------------|-------------------|-----------------------------|-----------------------------|
| **PUFAs** |                                  |                   |                   |                             |                             |
| AA       |                                  | 14.3 ± 0.4 (0.99) | 140'              | 107 (6)                     | 111 (9)                     |
| DHA      |                                  | 10.5 ± 0.8 (0.98) | 100'              | 108 (14)                    | 114 (12)                    |
| EPA      | 1; 5; 10; 25; 50'                 | 9.3 ± 0.5 (0.99)  | 150'              | 107 (8)                     | 112 (11)                    |
| LA       |                                  | 11 ± 1 (0.96)     | 200'              | 106 (12)                    | 113 (10)                    |
| alpha-LA |                                  | 15.2 ± 0.9 (0.99) | 90'               | 106 (10)                    | 108 (14)                    |
| **Isoprostanooids (IsoPs, NeuroPs, dihomo-isopPs), isofurans (IsoFs) and prostanoids (prostaglandins (PGs), leukotrienes (LEU), thromboxanes (TXs))** | | | | | |
| 5-F_{2a}-IsoP |                              | 0.52 ± 0.04 (0.99) | 15           | 88 (9)                       | 94 (6)                       |
| 8-epi-5-F_{2a}-IsoP |                          | 0.59 ± 0.07 (0.98) | 15           | 108 (10)                     | 98 (12)                      |
| 5-F_{2a}-IsoP |                              | 3.0 ± 0.4 (0.99)   | 10           | 98 (3)                       | 98 (11)                      |
| 8-epi-5-F_{2a}-IsoP |                          | 2.0 ± 0.3 (1)      | 5            | 110 (12)                     | 106 (10)                     |
| 5-F_{2a}-IsoP |                              | 2.7 ± 0.3 (0.97)   | 10           | 93 (13)                      | 106 (16)                     |
| 4(RS)-4-F_{2a}-NeuroP |                        | 1.40 ± 0.03 (0.98) | 15           | 112 (11)                     | 116 (11)                     |
| 20-F_{2a}-NeuroP |                          | 0.19 ± 0.01 (0.97) | 20           | 99 (14)                      | 98 (18)                      |
| 14(R,S)-4-F_{2a}-NeuroP |                       | 0.20 ± 0.03 (0.97) | 20           | 109 (2)                      | 116 (8)                      |
| 17-F_{2a}-dihomo-isoP |                        | 0.63 ± 0.01 (0.97) | 20           | 92 (17)                      | 108 (17)                     |
| 7(RS)-ST-Δ5-11-dihomo-isoF |                       | 0.16 ± 0.01 (0.98) | 10           | 108 (2)                      | 116 (10)                     |
| PG_E2 |                                 | 0.92 ± 0.08 (1)    | 10           | 82 (8)                       | 83 (11)                      |
| PG_D2 |                                 | 1.0 ± 0.3 (1)      | 15           | 99 (16)                      | 97 (11)                      |
| 15-deoxy-Δ_{12,14}-Prostaglandin L_{2a} | | 0.87 ± 0.04 (0.96) | 10           | 97 (8)                       | 103 (7)                      |
| LEU-B1 | 0.5; 5; 10; 25; 50 | 5.9 ± 0.3 (1) | 90           | 93 (8)                       | 92 (11)                      |
| TX-B2 | 0.5; 5; 10; 25; 50 | 0.68 ± 0.05 (1) | 50           | 103 (5)                      | 92 (9)                       |
| **Hydroxy/dihydroxy-PUFAs** | | | | | |
| 5-HETE | 13 ± 1 (1) | 460 | 112 (3) | 98 (6) |
| 12-HETE | 13.6 ± 0.6 (0.99) | 170 | 108 (2) | 103 (6) |
| 15-HETE | 21 ± 2 (0.99) | 180 | 104 (1) | 112 (8) |
| 20-HETE | 7 ± 1 (0.99) | 75 | 89 (14) | 86 (18) |
| 13-HODE | 16.8 ± 0.6 (0.99) | 170 | 104 (10) | 99 (16) |
| 8,9-DHETE | | | | | |
| 11,12-DHETE | | | | | |
| 14,15-DHETE | | | | | |
| **Epoxy-PUFAs** | | | | | |
| 8(9)-EET | 0.5 ± 0.1 (0.99) | 120 | 84 (3) | 78 (13) |
| 11(12)-EET | 1.9 ± 0.2 (1) | 70 | 84 (4) | 87 (12) |
| 14(15)-EET | 1.3 ± 0.1 (0.99) | 80 | 84 (9) | 85 (13) |
| **Pro-resolving (lipoxins, resolvins, maresins, protectins)** | | | | | |
| Lipoxin-A_{1} | | | | | |
| Lipoxin-A_{1} | | | | | |
| Resolvin-D_{1} | | | | | |
| Resolvin-D_{1} | | | | | |
| Resolvin-D_{1} | | | | | |
| Resolvin-D_{1} | | | | | |
| Resolvin-D_{2} | | | | | |
| Resolvin-D_{2} | | | | | |
| Resolvin-D_{2} | | | | | |
| Resolvin-D_{2} | | | | | |
| Resolvin-D_{2} | | | | | |
| Resolvin-D_{2} | | | | | |
| Resolvin-D_{2} | | | | | |
| Resolvin-D_{2} | | | | | |
| Resolvin-D_{2} | | | | | |
| Resolvin-D_{2} | | | | | |
| Resolvin-D_{2} | | | | | |
| Resolvin-D_{2} | | | | | |
| Resolvin-D_{2} | | | | | |
| Resolvin-D_{2} | | | | | |
| Resolvin-D_{2} | | | | | |
| Resolvin-D_{2} | | | | | |
| Resolvin-D_{2} | | | | | |
| Resolvin-D_{2} | | | | | |
| Resolvin-D_{2} | | | | | |
| Resolvin-D_{2} | | | | | |
| Resolvin-D_{2} | | | | | |
| Resolvin-D_{2} | | | | | |
| Resolvin-D_{2} | | | | | |
| Resolvin-D_{2} | | | | | |
| Resolvin-D_{2} | | | | | |
| Resolvin-D_{2} | | | | | |
| Resolvin-D_{2} | | | | | |
| Resolvin-D_{2} | | | | | |
| Resolvin-D_{2} | | | | | |
| Resolvin-D_{2} | | | | | |
| Resolvin-D_{2} | | | | | |
| Resolvin-D_{2} | | | | | |
| Resolvin-D_{2} | | | | | |
| Resolvin-D_{2} | | | | | |
| Resolvin-D_{2} | | | | | |
| Resolvin-D_{2} | | | | | |
| Resolvin-D_{2} | | | | | |
| Resolvin-D_{2} | | | | | |
| Resolvin-D_{2} | | | | | |
| Resolvin-D_{2} | | | | | |
| Resolvin-D_{2} | | | | | |
| Resolvin-D_{2} | | | | | |
| Resolvin-D_{2} | | | | | |
| Resolvin-D_{2} | | | | | |
| Resolvin-D_{2} | | | | | |
| Resolvin-D_{2} | | | | | |
| Resolvin-D_{2} | | | | | |
| Resolvin-D_{2} | | | | | |
| Resolvin-D_{2} | | | | | |
| Resolvin-D_{2} | | | | | |
| Resolvin-D_{2} | | | | | |
| Resolvin-D_{2} | | | | | |
| Resolvin-D_{2} | | | | | |
| Resolvin-D_{2} | | | | | |
| Resolvin-D_{2} | | | | | |
| Resolvin-D_{2} | | | | | |
| Resolvin-D_{2} | | | | | |
These compounds showed levels below LODs in ≥50% of samples, thus were not included in the statistical analysis.

*These slopes are referred to calibration curves prepared in plasma matrix due to the presence of a statistically significant (p < 0.05) matrix effect.

*Calculated from three replicates at low, medium, high (i.e. level 1st, 3rd, 5th of the calibration curve) concentration value.

Calculated from three replicates at low, medium, high (i.e. level 1st, 3rd, 5th of the calibration curve) concentration value in three days.

|                     | W  | Q₁  | Q₂  | Q₃  | Max  | p       |
|---------------------|----|-----|-----|-----|------|---------|
| **PUFAs**           |    |     |     |     |      |         |
| AA                  | 1457 | 8271 | 19456 | 27073 | 5025704 |         |
|                     | ICU | 989 | 90074 | 207975 | 473039 | 1745917 | 5.90E-03 |
| AdA                 | 112 | 421 | 608 | 1286 | 3135 |         |
|                     | ICU | 49 | 163 | 299 | 540 | 2333 | 1.59E-04 |
| DHA                 | 1370 | 5442 | 7892 | 15496 | 27073 | 97644 |         |
|                     | ICU | 611 | 1071 | 2227 | 4766 | 18899 | 1.33E-07 |
| DPA                 | 132 | 404 | 594 | 1248 | 6719 |         |
|                     | ICU | 36 | 175 | 258 | 616 | 3332 | 3.32E-04 |
| EPA                 | 365 | 1109 | 2602 | 4578 | 58599 |         |
|                     | ICU | 92 | 295 | 548 | 1031 | 6074 | 2.16E-06 |
| LA                  | 28932 | 93212 | 144014 | 233564 | 1144235 | 6.96E-08 |
|                     | ICU | 12213 | 33485 | 50050 | 81285 | 295489 |         |
| alpha-LA            | 534 | 2292 | 3308 | 6015 | 27592 |         |
|                     | ICU | 706 | 1237 | 2086 | 6955 | 23402 | 2.34E-01 |
| **Isoprostanoids (IsoPs, NeuroPs, dihomo-IsoPs), isofurans (IsoFs) and prostanoids (prostaglandins (PGs), leukotrienes (LEU), thromboxanes (TX))** |    |     |     |     |      |         |
| 5-F₂t-IsoP          | 0.046 | 0.463 | 1.14 | 2.20 | 6.00 |         |
|                     | ICU | 0.103 | 0.103 | 0.178 | 0.253 | 0.253 | 1.34E-01 |
| 5-epi-5-F₂t-IsoP    | 0.028 | 0.711 | 1.74 | 2.82 | 5.00 |         |
|                     | ICU | 0.055 | 0.126 | 0.269 | 0.641 | 1.31 | 3.80E-03 |
| 15-F₂t-IsoP         | 0.008 | 0.035 | 0.157 | 0.295 | 0.491 |         |
|                     | ICU | 0.013 | 0.028 | 0.069 | 0.219 | 1.61 | 4.14E-01 |
| 8-F₃t-IsoP          | 0.003 | 0.010 | 0.013 | 0.023 | 0.095 |         |
|                     | ICU | 0.002 | 0.005 | 0.008 | 0.014 | 0.016 | 8.25E-03 |
| 15-E₂t-IsoP         | 0.006 | 0.173 | 0.334 | 0.514 | 2.03 |         |
|                     | ICU | 0.002 | 0.006 | 0.014 | 0.037 | 0.201 | 9.50E-11 |
| 4(R,S)-4-F₃t-NeuroP | 0.007 | 0.092 | 0.238 | 0.594 | 1.61 |         |
|                     | ICU | 0.005 | 0.020 | 0.026 | 0.074 | 0.263 | 1.39E-05 |
| 20-F₆t-NeuroP       | 0.031 | 0.174 | 0.251 | 0.513 | 1.15 |         |
|                     | ICU | 0.021 | 0.036 | 0.068 | 0.116 | 0.149 | 9.08E-05 |
| 20-epi-20-F₆t-NeuroP| 0.055 | 0.240 | 0.311 | 0.548 | 1.74 |         |
|                     | ICU | 0.065 | 0.195 | 0.512 | 0.795 | 2.46 | 3.76E-01 |
| 14(R,S)-14-F₆t-NeuroP| 0.019 | 0.236 | 0.532 | 0.886 | 1.75 |         |
|                     | ICU | 0.037 | 0.109 | 0.200 | 0.308 | 0.724 | 2.67E-02 |
| Compound | W     | ICU   |
|----------|-------|-------|
| 14(R,S)-14-F_2-NeuroP | 0.004 | 0.007 |
| ent-7(R,S)-7-F_2-dihomo- IsoP | 0.006 | 0.061 |
| 7(R,S)-ST-Δ^5-11-dihomo- IsoF | 0.133 | 0.061 |
| PGE_2 | 0.018 | 0.009 |
| PGD_2 | 0.011 | 0.011 |
| LEU-B_4 | 0.089 | 0.054 |
| TX-B_2 | 0.045 | 0.019 |
| Hydroxy/di-hydroxy-PUFAs |       |       |
| 5-HETE | 0.292 | 0.067 |
| 12-HETE | 0.593 | 0.078 |
| 15-HETE | 0.363 | 0.080 |
| 20-HETE | 0.049 | 0.019 |
| 13-HODE | 19.6  | 8.35  |
| 8,9-DiHETE | 0.009 | 0.001 |
| 11,12-DiHETE | 0.006 | 0.005 |
| 14,15-DiHETE | 0.007 | 0.004 |
| Epoxy-PUFAs |       |       |
| 8(9)-EET | 0.073 | 0.064 |
| 11(12)-EET | 0.046 | 0.029 |
| 14(15)-EET | 0.054 | 0.068 |
| Pro-resolving (lipoxins, resolvins, maresins, protectins) |       |       |
| Lipoxin-A_4 | 0   | 0.001 |
| Lipoxin-B_4 | 0.016 | 0.003 |
Table S4. Cytokine concentration levels (pg/mL) in COVID-19 ward (W, n=43) and ICU (ICU, n=27) samples: minimum (Min), first quartile (Q1), median (Q2), third quartile (Q3), maximum (Max), p value (p) from Student’s t-test (difference between means) on log-transformed data.

| Cytokine          | W Min | W Q1 | W Q2 | W Q3 | W Max | ICU Min | ICU Q1 | ICU Q2 | ICU Q3 | ICU Max | p      |
|-------------------|-------|------|------|------|-------|---------|--------|--------|--------|---------|--------|
| IL-6              | 2.7   | 12.7 | 20.1 | 42.7 | 602   | 1.3     | 15.8   | 53.0   | 129    | 614     | 0.332  |
| IL-1β             | 0.2   | 0.7  | 0.9  | 1.5  | 31.0  | 0.2     | 0.7    | 1.2    | 2.1    | 16.4    | 0.363  |
| IL-10             | 0.2   | 1.0  | 2.7  | 3.4  | 324   | 0.4     | 1.0    | 3.4    | 5.4    | 15.8    | 0.949  |
| TNF-α             | 3.3   | 5.5  | 7.8  | 15.2 | 32.5  | 0.6     | 2.8    | 8.5    | 20.0   | 50.3    | 0.363  |
| CCL2              | 175   | 357  | 600  | 910  | 3950  | 172     | 411    | 630    | 1852   | 3971    | 0.254  |
Figure S1. Chromatographic profile of the sixty individual oxylipins (Quantifier transition) detected in a representative plasma sample of COVID-19 patient (orange line), as well as in standard solution, with comparable concentration levels (blue line).
Figure S2. Scatter column plot of log-transformed isoprostanoids derived from different classes (i.e. \( F_2 \)-IsoPs, \( F_2 \)-dihomo-IsoPs, NeuroPs), as well as from different precursors (i.e. \( \omega-3 \) vs. \( \omega-6 \)-PUFAs) in ICU and W samples (training and test set). For each class, compounds were combined by sum.
Figure S3. Scatter column plot of log-transformed individual oxylipins quantified in ICU and W samples (training and test set).
175
Figure S4. ROC curves of the best performing oxylipins in the classification of samples: 20-epi-20-F_{4t}-NeuroP (top, AUC = 0.78) and 5-F_{2t}-IsoP (bottom, AUC = 0.88). FP = false positives; TP = true positives.
1. Oger C, Brinkmann Y, Bouazzaoui S, Durand T, Galano JM. Stereocontrolled access to isoprostanes via a bicyclo[3.3.0]octene framework. Organic Letters. 2008;10:5087–90.

2. Balas L, Durand T. Dihydroxylated E, E, Z-docosatrienes. An overview of their synthesis and biological significance. Progress in lipid research. Elsevier; 2016;61:1–18.

3. Balas L, Risé P, Gandrath D, Rovati G, Bolego C, Stellari F, et al. Rapid metabolization of protectin D1 by β-oxidation of its polar head chain. Journal of medicinal chemistry. ACS Publications; 2019;62:9961–75.
Table S1. Full list of quantified oxylipins, MRM transitions and the corresponding labelled internal standards used for the quantification.

| Compound | Internal standard | MRM quantifier (Q) transition (precursor ion → product ion (CE, V)) | MRM qualifier (q) transition (precursor ion → product ion (CE, V)) |
|----------|------------------|---------------------------------------------------------------|---------------------------------------------------------------|
| **PUFAs** |                  |                                                               |                                                               |
| AA       | LA-d4            | 303 → 259 (12)                                                | 303 → 285 (28)                                                |
| AdA      | LA-d4            | 331 → 331 (1)                                                 |                                                               |
| DHA      | LA-d4            | 327 → 283 (8)                                                 | 327 → 229 (10)                                                |
| DPA      | LA-d4            | 329 → 285 (12)                                                | 329 → 231 (8)                                                 |
| EPA      | LA-d4            | 301 → 257 (12)                                                | 301 → 203 (16)                                                |
| LA       | LA-d4            | 279 → 279 (1)                                                 |                                                               |
| alpha-LA | LA-d4            | 277 → 277 (1)                                                 |                                                               |
| Isoprostanoïds (IsoPs, NeuroPs, dihomo-isopPs), isofurans (IsoFs) and prostanoids (prostaglandins (PGs), leukotrienes (LEU), thromboxanes (TXs)) | | |
| 5-F_{2}-IsoP | 15-F_{2}-IsoP-d4 | 353 → 309 (20) | 353 → 115 (31) |
| 5-epi-5-F_{2}-IsoP | 15-F_{2}-IsoP-d4 | 353 → 309 (20) | 353 → 115 (31) |
| 15-F_{2}-IsoP | 15-F_{2}-IsoP-d4 | 353 → 193 (28) | 353 → 309 (20) |
| 8-F_{3}-IsoP | C21 15-F_{2}-IsoP | 351 → 127 (28) | 351 → 155 (28) |
| 8-epi-8-F_{3}-IsoP | C21 15-F_{2}-IsoP | 351 → 127 (28) | 351 → 155 (28) |
| 18-F_{3}-IsoP | C21 15-F_{2}-IsoP | 351 → 233 (28) | 351 → 289 (28) |
| 15-E_{4}-IsoP | 15-E_{2}-IsoP-d4 | 351 → 315 (8) | 351 → 271 (28) |
| 4(R,S)-4-F_{2}-NeuroP | 10-F_{2}-NeuroP-d4 | 377 → 271 (25) | 377 → 101 (25) |
| 20-F_{2}-NeuroP | 10-F_{2}-NeuroP-d4 | 377 → 239 (27) | 377 → 323 (27) |
| 20-epi-20-F_{2}-NeuroP | 10-epi-F_{4}-NeuroP-d4 | 377 → 271 (28) | 377 → 315 (28) |
| 14(R,S)-14-F_{2}-NeuroP | 10-F_{2}-NeuroP-d4 | 377 → 161 (28) | 377 → 205 (28) |
| 14(R,S)-14-F_{2}-NeuroP | 10-F_{2}-NeuroP-d4 | 379 → 179 (30) | 379 → 207 (30) |
| ent-7(R,S)-7-F_{2}-dihomo-isof | 17(R)-Resolvin-D_{1}-d5 | 381 → 143 (34) | 381 → 319 (34) |
| 17-F_{2}-dihomo-isof | 17(R)-Resolvin-D_{1}-d5 | 381 → 337 (31) | 381 → 237 (31) |
| 7(R,S)-ST-A^∗-11-dihomo-isof | 17(R)-Resolvin-D_{1}-d5 | 397 → 201 (36) | 397 → 143 (36) |
| PGE_{2} | PGE_{2}-d4 | 351 → 315 (8) | 351 → 271 (28) |
| PGD_{2} | PGE_{2}-d4 | 351 → 315 (12) | 351 → 271 (20) |
| 15-deoxy-A^12,14-Prostaglandin J_{2} | PGE_{2}-d4 | 315 → 271 (12) | 315 → 203 (24) |
| LEU-B_{1} | Maresin 1-d5 | 335 → 195 (16) | 335 → 317 (16) |
| TX-B_{2} | 15-F_{2}-IsoP-d4 | 369 → 195 (12) | 369 → 169 (20) |
| **Hydroxy/dihydroxy-PUFAs** | | | |
| 5-HETE | 20-HETE-d6 | 319 → 115 (12) | 319 → 257 (12) |
| 12-HETE | 20-HETE-d6 | 319 → 179 (12) | 319 → 208 (12) |
| 15-HETE | 20-HETE-d6 | 319 → 219 (12) | 319 → 175 (16) |
| 20-HETE | 20-HETE-d6 | 319 → 289 (16) | 319 → 245 (16) |
| 15-HODE | 20-HETE-d6 | 295 → 277 (20) | 295 → 195 (16) |
| 8,9-DiHETE | Maresin 1-d5 | 335 → 185 (16) | 335 → 127 (24) |
| 11,12-DiHETE | Maresin 1-d5 | 335 → 167 (16) | 335 → 207 (20) |
| 14,15-DiHETE | Maresin 1-d5 | 335 → 317 (12) | 335 → 207 (20) |
| **Epoxy-PUFAs** | | | |
| 8(9)-EET | 14(15)-EET-d11 | 319 → 155 (12) | 319 → 257 (8) |
| 11(12)-EET | 14(15)-EET-d11 | 319 → 167 (12) | 319 → 179 (12) |
| 14(15)-EET | 14(15)-EET-d11 | 319 → 219 (8) | 319 → 257 (8) |
| **Pro-resolving (lipoxins, resolvins, maresins, protectins)** | | | |
| Lipoxin-A_{1} | Lipoxin-A_{1}-d5 | 351 → 115 (16) | 351 → 235 (14) |
| Lipoxin-A_{2} | Lipoxin-A_{2}-d5 | 351 → 221 (16) | 351 → 233 (16) |
| Resolvin-D_{1} | Resolvin-D_{1}-d5 | 375 → 141 (14) | 375 → 233 (14) |
| Resolvin-D_{2} | Resolvin-D_{2}-d5 | 375 → 175 (18) | 375 → 141 (14) |
| Resolvin-D_{3} | Resolvin-D_{3}-d5 | 375 → 147 (18) | 375 → 191 (18) |
| Resolvin-D_{4} | Resolvin-D_{4}-d5 | 375 → 101 (16) | 375 → 357 (16) |
| Resolvin-D_{5} | Maresin 1-d5 | 359 → 199 (16) | 359 → 279 (16) |
| 17(R)-Resolvin-D_{1} | 17(R)-Resolvin-D_{1}-d5 | 375 → 141 (14) | 375 → 233 (14) |
| 17(R)-Resolvin-D_{2} | 17(R)-Resolvin-D_{2}-d5 | 375 → 147 (18) | 375 → 191 (18) |
| 17(R)-Resolvin-D_{3} | 17(R)-Resolvin-D_{3}-d5 | 375 → 101 (16) | 375 → 357 (16) |
| Resolvin-E_{1} | Resolvin-E_{1}-d5 | 349 → 195 (16) | 349 → 205 (16) |
| Maresin-1 | Maresin 1-d5 | 359 → 177 (16) | 359 → 250 (16) |
| 7-epi-maresin-1 | Maresin 1-d5 | 359 → 250 (18) | 359 → 177 (18) |
| Compound                | Form          | Mass 1 → Mass 2 (R) | Mass 1 → Mass 3 (R) |
|-------------------------|---------------|---------------------|---------------------|
| Maresin-2               | Maresin 1-d5  | 359 → 221 (14)      | 359 → 232 (16)      |
| Neuroprotectin D₁       | Maresin 1-d5  | 359 → 206 (14)      | 359 → 153 (14)      |
| dinor-Neuroprotectin D₁ | Maresin 1-d5  | 333 → 315 (14)      | 333 → 206 (21)      |
| Tetrnor-Neuroprotectin D₁ | Maresin 1-d5 | 305 → 243 (16)      | 305 → 192 (16)      |
| Protectin DX            | Maresin 1-d5  | 359 → 153 (14)      | 359 → 206 (14)      |
| diH-AdA                 | Maresin 1-d5  | 363 → 345 (21)      | 363 → 208 (21)      |
| diH₆,₇-DPA              | Maresin 1-d5  | 361 → 263 (16)      | 361 → 206 (18)      |
| diH₆,₇-DPA              | Maresin 1-d5  | 361 → 153 (18)      | 361 → 208 (21)      |
| Linotrin                | Maresin 1-d5  | 309 → 291 (21)      | 309 → 171 (21)      |
Table S2. Full list of quantified oxylipins and relevant analytical parameters (calibration curve, limit of detection, intra-assay and inter-assay recovery, intra-assay and inter-assay precision.

| Compound               | Calibration levels (pg/mL, ng/mL) | LOD (pg/mL, ng/mL) | Intra-assay recovery % (RSD) | Inter-assay recovery % (RSD) |
|------------------------|-----------------------------------|--------------------|-----------------------------|-----------------------------|
| **PUFAs**              |                                   |                    |                             |                             |
| AA                     | 14.3 ± 0.4 (0.99)^b                | 10                  | 111 (9)                     |                              |
| AdA                    | 12.1 ± 1 (0.97)^b                  | 60                  | 106 (3)                     |                              |
| DHA                    | 10.5 ± 0.8 (0.98)^b                | 100                 | 114 (12)                    |                              |
| EPA                    | 16.2 ± 2 (0.99)^b                  | 50                  | 107 (16)                    |                              |
| LA                     | 9.3 ± 0.5 (0.99)^b                 | 150                 | 112 (11)                    |                              |
| alpha-LA               | 11.1 ± 1 (0.96)^b                  | 200                 | 113 (10)                    |                              |
| **Isoprostanooids (IsopPs, NeuroPs, dihomo-IsopPs), isofurans (IsoFs) and prostanoids (prostaglandins (PGs), leukotrienes (LEU), thromboxanes (TX))** |                                   |                    |                             |                             |
| 5-F_{2}E-isop P        | 14.3 ± 0.4 (0.99)^b                | 15                  | 94 (6)                      |                              |
| 5-epi-5-F_{2}E-isop P  | 0.52 ± 0.04 (0.99)^b               | 15                  | 98 (12)                     |                              |
| 15-F_{2}E-isop P       | 3.0 ± 0.4 (0.99)^b                 | 10                  | 98 (12)                     |                              |
| 8-F_{2}E-isop P        | 2.0 ± 0.3 (1)                      | 5                   | 106 (10)                    |                              |
| 8-epi-8-F_{2}E-isop P  | 2.0 ± 0.2 (0.99)                   | 5                   | 108 (10)                    |                              |
| 18-F_{2}E-isop P       | 0.48 ± 0.08 (0.98)^b               | 10                  | 98 (15)                     |                              |
| 15-E_{2}E-isop P       | 2.7 ± 0.3 (0.97)^b                 | 10                  | 106 (16)                    |                              |
| 4(RS)-4-F_{2}E-Neuro P | 0.50; 0.10; 0.25; 0.50; 1          | 1.40 ± 0.03 (0.98)  | 150                         | 116 (11)                     |
| 20-F_{2}E-Neuro P      | 0.19 ± 0.01 (0.97)^b               | 20                  | 99 (14)                     | 116 (11)                     |
| 20-epi-20-F_{2}E-Neuro P| 0.32 ± 0.01 (0.94)^d               | 60                  | 116 (10)                    |                              |
| 14(RS)-14-F_{2}E-Neuro P| 0.20 ± 0.03 (0.97)^c               | 20                  | 92 (17)                     | 116 (10)                     |
| 14(RS)-14-F_{2}E-Neuro P| 0.63 ± 0.01 (0.97)^d               | 20                  | 92 (17)                     | 116 (10)                     |
| ent-(7R,7S)-7-F_{2}E-dihomo-isop | 0.88 ± 0.08 (0.98)^b | 10 | 94 (14) |                              |
| 7r,5s-dihomo-isop P    | 1.2 ± 0.1 (0.99)                   | 20                  | 96 (10)                     |                              |
| 15-F_{2}E-dihomo-isop P| 0.16 ± 0.01 (0.98)^c               | 10                  | 92 (16)                     |                              |
| 15-deoxy-A_{2b,3h}-Prostaglandin J | 0.87 ± 0.4 (0.98)^b | 10 | 93 (8) | 103 (7) |
| LEU-B_{1}              | 0.5 ± 0.08 (0.97)^c               | 10                  | 92 (8)                      | 116 (10)                     |
| TX-B_{1}               | 0.68 ± 0.05 (0.98)                 | 50                  | 92 (9)                      |                              |
| **Hydroxy/dihydroxy-PUFAs** |                               |                    |                             |                             |
| 5-HETE                 | 13 ± 1 (1)^c                       | 460                 | 98 (6)                      |                              |
| 12-HETE                | 13.6 ± 2.6 (0.99)^c                | 170                 | 103 (6)                     |                              |
| 15-HETE                | 2.1 ± 2 (0.99)^c                   | 180                 | 114 (12)                    |                              |
| 20-HETE                | 7 ± 1 (0.99)                       | 75                  | 85 (14)                     | 96 (10)                      |
| 13-HODE                | 16.8 ± 0.6 (0.99)                  | 1                   | 109 (10)                    | 99 (16)                      |
| 8,9-DiHETE             | 5.71 ± 0.04 (1)                    | 10                  | 87 (10)                     |                              |
| 11,12-DiHETE           | 21.2 ± 0.5 (1)                     | 70                  | 83 (13)                     |                              |
| 14,15-DiHETE           | 16 ± 1 (1)                         | 60                  | 94 (12)                     | 86 (14)                      |
| **Epoxy-PUFAs**        |                                   |                    |                             |                             |
| 8(9)-EET               | 0.5 ± 0.1 (0.99)                   | 120                 | 98 (13)                     |                              |
| 11(12)-EET             | 1.9 ± 0.2 (1)                      | 70                  | 98 (12)                     |                              |
| 14(15)-EET             | 1.3 ± 0.1 (0.99)                   | 80                  | 98 (13)                     |                              |
| **Pro-resolving (lipoxins, resolvins, maresins, protectins)** |                               |                    |                             |                             |
| Lipoxin-A_{1}          | 10.0 ± 0.5 (0.99)^b                | 5                   | 107 (15)                    |                              |
| Lipoxin-B_{1}          | 1.4 ± 0.2 (0.98)^c                 | 10                  | 107 (9)                     | 86 (16)                      |
| Resolvins-D_{1}        | 1.00 ± 0.03 (0.99)                 | 10                  | 107 (12)                    |                              |
| Resolvins-D_{2}        | 0.25 ± 0.02 (0.99)                 | 5                   | 93 (11)                     |                              |
| Resolvins-D_{3}        | 1.3 ± 0.1 (0.99)                   | 10                  | 96 (16)                     |                              |
| Resolvins-D_{4}        | 0.45 ± 0.06 (0.99)^b               | 20                  | 97 (11)                     |                              |
| Resolvins-D_{5}        | 5.4 ± 0.7 (1)                      | 20                  | 98 (12)                     |                              |
| 17(R)-Resolvins-D_{2}  | 1.4 ± 0.2 (1)                      | 10                  | 98 (12)                     |                              |
| 17(R)-Resolvins-D_{3}  | 1.2 ± 0.2 (0.99)                   | 5                   | 93 (7)                      | 88 (10)                      |
| 17(R)-Resolvins-D_{4}  | 0.45 ± 0.06 (0.99)^b               | 20                  | 107 (13)                    |                              |
| 17(R)-Resolvins-D_{5}  | 1.6 ± 0.2 (0.99)                   | 15                  | 106 (12)                    |                              |
| 7-epi-maresin-1^a      | 1.0 ± 0.08 (1)                     | 15                  | 93 (12)                     |                              |
| Maresin-2              | 3.9 ± 0.4 (1)^c                    | 15                  | 91 (5)                      |                              |
| Neuroprotectin D_{1}   | 4.9 ± 0.1 (1)^c                    | 20                  | 88 (15)                     |                              |
| dinor-Neuroprotectin D_{1} | 5.3 ± 0.3 (0.99)^c | 100 | 115 (14) |                              |
| Tetrano-Neuroprotectin D_{1} | 0.5 ± 0.1 (0.98)^c | 150 | 115 (14) |                              |
| Protectin DX           | 0.10 ± 0.6 (1)^c                   | 15                  | 109 (15)                    |                              |
| diH-AdA                | 2.7 ± 0.2 (0.99)^c                 | 30                  | 93 (14)                     |                              |
These compounds showed levels below LODs in ≥ 50% of samples, thus were not included in the statistical analysis.

These slopes are referred to calibration curves prepared in plasma matrix due to the presence of a statistically significant (p < 0.05) matrix effect.

1 Calculated from three replicates at low, medium, high (i.e. level 1st, 2nd, 3rd of the calibration curve) concentration value.

2 Calculated from three replicates at low, medium, high (i.e. level 1st, 2nd, 3rd of the calibration curve) concentration value in three days.

| Compound          | Mean ± SEM (n) | LOQ 1  | LOQ 2  | LOQ 3  |
|-------------------|---------------|--------|--------|--------|
| diH<sub>n</sub>-3-DPA<sup>a</sup> | 2.81 ± 0.01 (1) | 20     | 84 (15) | 85 (12) |
| diH<sub>n</sub>-6-DPA<sup>a</sup> | 7.2 ± 0.9 (1)<sup>b</sup> | 30     | 108 (8) | 109 (16) |
| Linotrin<sup>a</sup> | 16 ± 2 (0.99)<sup>b</sup> | 20     | 108 (5) | 112 (11) |

<sup>a</sup> These compounds showed levels below LODs in ≥ 50% of samples, thus were not included in the statistical analysis.

<sup>b</sup> These slopes are referred to calibration curves prepared in plasma matrix due to the presence of a statistically significant (p < 0.05) matrix effect.

<sup>c</sup> Calculated from three replicates at low, medium, high (i.e. level 1st, 2nd, 3rd of the calibration curve) concentration value.

<sup>d</sup> Calculated from three replicates at low, medium, high (i.e. level 1st, 2nd, 3rd of the calibration curve) concentration value in three days.
Table S3. Oxylipin concentration levels (ng/mL) in COVID-19 ward (W, n=43) and ICU (ICU, n=27) samples: minimum (Min), first quartile (Q1), median (Q2), third quartile (Q3), maximum (Max), p value (p) from Student’s t-test (difference between means) on log-transformed data.

| PUFA | Min | Q1 | Q2 | Q3 | Max | p       |
|------|-----|----|----|----|-----|---------|
| AA   | W 1457 | 8271 | 19456 | 27073 | 5025704 |         |
|      | ICU 989 | 90074 | 207975 | 473039 | 1745917 | 5.90E-03 |
| AdA  | W 112 | 421 | 608 | 1286 | 3135 |         |
|      | ICU 49 | 163 | 299 | 540 | 2333 | 1.59E-04 |
| DHA  | W 1370 | 5442 | 7892 | 15496 | 79644 |         |
|      | ICU 611 | 1071 | 2227 | 4766 | 18899 | 1.33E-07 |
| DPA  | W 132 | 404 | 594 | 1248 | 6719 |         |
|      | ICU 36 | 175 | 258 | 616 | 3332 | 3.32E-04 |
| EPA  | W 365 | 1109 | 2602 | 4578 | 58599 |         |
|      | ICU 92 | 295 | 548 | 1031 | 6074 | 2.16E-06 |
| LA   | W 28932 | 93212 | 144014 | 233564 | 1144235 |         |
|      | ICU 12213 | 33485 | 50050 | 81285 | 295489 | 6.96E-08 |
| alpha-LA | W 534 | 2292 | 3308 | 6015 | 27592 |         |
|      | ICU 706 | 1237 | 2086 | 6955 | 23402 | 2.34E-01 |

Isoprostanoids (IsoPs, NeuroPs, dihomo-IsoPs), isofurans (IsoFs) and prostanoids (prostaglandins (PGs), leukotrienes (LEU), thromboxanes (TX))

| IsoP | Min | Q1 | Q2 | Q3 | Max | p       |
|------|-----|----|----|----|-----|---------|
| 5-F_{2alpha}-IsoP | W 0.046 | 0.463 | 1.14 | 2.20 | 6.00 |         |
|      | ICU 0.103 | 0.103 | 0.178 | 0.253 | 0.253 | 1.34E-01 |
| 5-epi-5-F_{2alpha}-IsoP | W 0.028 | 0.711 | 1.74 | 2.82 | 5.00 |         |
|      | ICU 0.055 | 0.126 | 0.269 | 0.641 | 1.31 | 3.80E-03 |
| 15-F_{2alpha}-IsoP | W 0.008 | 0.035 | 0.157 | 0.295 | 0.491 |         |
|      | ICU 0.013 | 0.028 | 0.069 | 0.219 | 1.61 | 4.14E-01 |
| 8-F_{2alpha}-IsoP | W 0.003 | 0.010 | 0.013 | 0.023 | 0.095 |         |
|      | ICU 0.002 | 0.005 | 0.008 | 0.014 | 0.016 | 8.25E-03 |
| 15-E_{2alpha}-IsoP | W 0.006 | 0.173 | 0.334 | 0.514 | 2.03 |         |
|      | ICU 0.002 | 0.006 | 0.014 | 0.037 | 0.201 | 9.50E-11 |
| 4(R.S)-4-F_{2alpha}-NeuroP | W 0.007 | 0.092 | 0.238 | 0.594 | 1.61 |         |
|      | ICU 0.005 | 0.020 | 0.026 | 0.074 | 0.263 | 1.39E-05 |
| 20-F_{2alpha}-NeuroP | W 0.031 | 0.174 | 0.251 | 0.513 | 1.15 |         |
|      | ICU 0.021 | 0.036 | 0.068 | 0.116 | 0.149 | 9.08E-05 |
| 20-epi-20-F_{2alpha}-NeuroP | W 0.055 | 0.240 | 0.311 | 0.548 | 1.74 |         |
|      | ICU 0.065 | 0.195 | 0.512 | 0.795 | 2.46 | 3.76E-01 |
| 14(R.S)-14-F_{2alpha}-NeuroP | W 0.019 | 0.236 | 0.532 | 0.886 | 1.75 |         |
|      | ICU 0.037 | 0.109 | 0.200 | 0.308 | 0.724 | 2.67E-02 |
| 14(R.S)-14-F_{2alpha}-NeuroP | W 0.004 | 0.074 | 0.144 | 0.337 | 0.695 |         |
|      | ICU 0.007 | 0.025 | 0.038 | 0.078 | 0.191 | 1.99E-03 |
| ent-7(R.S)-7-F_{2alpha}-dihomo-IsoP | W 0.006 | 0.020 | 0.033 | 0.065 | 3.78 |         |
|      | ICU 0.061 | 0.082 | 0.099 | 0.147 | 0.183 | 1.89E-04 |
| 7(R.S)-ST-Δ^{11}-11-dihomo-IsoF | W 0.133 | 1.17 | 1.65 | 2.22 | 5.33 |         |
|                  | ICU   | W    |
|------------------|-------|------|
| PGE₂             | 0.061 | 0.157| 0.313 | 1.58  | 10.8 | 2.91E-03 |
| PGD₂             | 0.009 | 0.016| 0.025 | 0.106 | 0.567| 8.14E-10 |
| LEU-B₄           | 0.089 | 9.54 | 58.3  | 70.6  | 221  | 3.24E-10 |
| TX-B₂            | 0.045 | 0.174| 0.283 | 0.595 | 1.97 | 9.93E-01 |

### Hydroxy/di-hydroxy-PUFAs

|                | ICU   | W    |
|----------------|-------|------|
| 5-HETE         | 0.292 | 2.32 | 49.1  | 139   | 539  | 6.34E-09 |
| 12-HETE        | 0.593 | 3.27 | 25.4  | 62.8  | 481  | 1.27E-05 |
| 15-HETE        | 0.563 | 2.56 | 24.7  | 82.8  | 433  | 1.37E-08 |
| 20-HETE        | 0.049 | 0.090| 0.136 | 0.199 | 0.891| 1.95E-02 |
| 13-HODE        | 0.009 | 0.029| 0.049 | 0.066 | 0.348| 1.27E-05 |
| 8,9-DHETE      | 0.009 | 0.029| 0.049 | 0.066 | 0.348| 1.27E-05 |
| 11,12-DiHETE   | 0.005 | 0.016| 0.030 | 0.055 | 0.290| 1.29E-02 |
| 14,15-DiHETE   | 0.004 | 0.009| 0.014 | 0.029 | 0.155| 1.29E-02 |

### Epoxy-PUFAs

|                | ICU   | W    |
|----------------|-------|------|
| 8(9)-EET       | 0.073 | 0.258| 0.712 | 1.61  | 8.18 | 1.86E-04 |
| 11(12)-EET     | 0.046 | 0.121| 0.264 | 0.510 | 3.18 | 5.50E-07 |
| 14(15)-EET     | 0.054 | 0.162| 0.517 | 1.61  | 4.43 | 4.59E-06 |

### Pro-resolving (lipoxins, resolvins, maresins, protectins)

|                | ICU   | W    |
|----------------|-------|------|
| Lipoxin-A₄     | 0     | 0.012| 0.038 | 0.110 | 0.588| 1.10E-01 |
| Lipoxin-B₄     | 0.016 | 0.384| 1.07  | 1.89  | 2.90 | 1.87E-04 |
| Resolvin-D₁     | 0.002 | 0.031| 0.170 | 0.482 | 1.78 | 5.02E-05 |
| Resolvin-D₂     | 0.003 | 0.079| 0.178 | 1.02  | 2.97 | 1.50E-02 |
| Resolvin-D₃     | 0.021 | 0.632| 1.73  | 3.95  | 31.0|
|                      | ICU  |        |        |        |        |        |
|----------------------|------|--------|--------|--------|--------|--------|
|                      | 0.005 | 0.038  | 0.091  | 0.489  | 3.15   | 3.88E-08 |
| 17(\(R\))-Resolvin-D\(_1\) |      |        |        |        |        |        |
| W                    | 0.010 | 0.213  | 0.385  | 0.529  | 1.65   |
| ICU                  | 0.001 | 0.010  | 0.024  | 0.070  | 0.931  | 1.79E-07 |
| 17(\(R\))-Resolvin-D\(_3\) |      |        |        |        |        |        |
| W                    | 0.003 | 0.195  | 0.286  | 0.390  | 0.911  |
| ICU                  | 0.001 | 0.006  | 0.024  | 0.072  | 0.242  | 5.93E-08 |
| Maresin-1            | W    | 0.108  | 1.08   | 2.31   | 3.76   | 33.0   |
| ICU                  | 0.064 | 0.106  | 0.503  | 0.697  | 3.31   | 6.84E-04 |
| Maresin-2            | W    | 0.010  | 0.137  | 0.370  | 1.18   | 19.1   |
| ICU                  | 0.011 | 0.017  | 0.025  | 0.073  | 0.452  | 1.31E-08 |
| Neuroprotectin D\(_1\) | W    | 0.041  | 1.89   | 5.20   | 8.16   | 66.7   |
| ICU                  | 0.010 | 0.027  | 0.049  | 0.255  | 0.341  | 1.15E-08 |
| dinor-Neuroprotectin D\(_1\) | W    | 0.096  | 2.04   | 9.65   | 20.4   | 116    |
| ICU                  | 0.058 | 0.146  | 0.275  | 0.503  | 2.90   | 6.60E-12 |
| Protectin DX         | W    | 0.010  | 0.976  | 3.21   | 5.96   | 41.9   |
| ICU                  | 0.009 | 0.037  | 0.086  | 0.707  | 5.26   | 2.80E-08 |
| diH-AdA              | W    | 0.008  | 0.143  | 0.517  | 1.11   | 16.2   |
| ICU                  | 0.008 | 0.044  | 0.066  | 0.084  | 0.088  | 7.07E-03 |
| Linotrin             | W    | 0.016  | 0.042  | 0.102  | 0.173  | 0.580  |
| ICU                  | 0.007 | 0.021  | 0.049  | 0.115  | 0.497  | 2.23E-02 |
Table S4. Cytokine concentration levels (pg/mL) in COVID-19 ward (W, n=43) and ICU (ICU, n=27) samples: minimum (Min), first quartile (Q1), median (Q2), third quartile (Q3), maximum (Max), p value (p) from Student’s t-test (difference between means) on log-transformed data.

|       | Min   | Q1   | Q2   | Q3   | Max   | p     |
|-------|-------|------|------|------|-------|-------|
| IL-6  |       |      |      |      |       |       |
| W     | 2.7   | 12.7 | 20.1 | 42.7 | 602   |       |
| ICU   | 1.3   | 15.8 | 53.0 | 129  | 614   | 0.332 |
| IL-1β |       |      |      |      |       |       |
| W     | 0.2   | 0.7  | 0.9  | 1.5  | 31.0  |       |
| ICU   | 0.2   | 0.7  | 1.2  | 2.1  | 16.4  | 0.363 |
| IL-10 |       |      |      |      |       |       |
| W     | 0.2   | 1.0  | 2.7  | 3.4  | 324   |       |
| ICU   | 0.4   | 1.0  | 3.4  | 5.4  | 15.8  | 0.949 |
| TNF-α |       |      |      |      |       |       |
| W     | 3.3   | 5.5  | 7.8  | 15.2 | 32.5  |       |
| ICU   | 0.6   | 2.8  | 8.5  | 20.0 | 50.3  | 0.363 |
| CCL2  |       |      |      |      |       |       |
| W     | 175   | 357  | 600  | 910  | 3950  |       |
| ICU   | 172   | 411  | 630  | 1852 | 3971  | 0.254 |